BioSpace News Archive

Absorption Systems, a global leader in the science of translational medicine, announces that the Japanese Patent Office has issued a Decision to Grant a patent covering the In Vitro Dissolution Absorption System (IDAS2™), a groundbreaking, first-in-class technology.

“I wanted to prevent the formation of bed sores upon the feet,” said an inventor from Beaconsfield, Quebec, Canada. “This led me to come up with a way to keep pressure off sensitive areas so that ulceration would not occur. It also helps to heal already existing sores by taking the pressure off. Sores cannot heal unless the pressure is alleviated.”

Clapp Communications, a Baltimore-based, award-winning advertising, marketing, digital and public relations firm, is pleased to announce Melbourne Athletic Club (MAC) as its newest client.

AdvanSource Biomaterials Corporation (OTCQB: ASNB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced that the Company has entered into a multi-million dollar amendment of the current supply, royalty and license agreement with Access Scientific

WellBridge Healthcare is pleased to announce that Soni Helmicki has been appointed Chief Executive Officer of the WellBridge Hospital in Fort Worth. Ms. Helmicki is an esteemed behavioral health executive with extensive experience in the North Texas area.

QIAGEN N.V. announces that it will initiate the repurchase of a second tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018.

Repro Med Systems, Inc. dba RMS Medical Products today announced that Donald B. Pettigrew has been appointed to the position of President and Chief Commercial Officer.

Statistically significant reduction in cough frequency observed among IPF patients after 14 days of treatment in completed Phase 2a trial

Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has been awarded £637k funding under the Innovate UK Biomedical Catalyst Primer Award scheme.